ISMOTIC NEWS HIGHLIGHTS Media Articles Related to Ismotic (Isosorbide)
isosorbide mononitrate, Imdur, Ismo, Monoket
Source: MedicineNet isosorbide dinitrate Specialty [2009.03.26]
Title: isosorbide mononitrate, Imdur, Ismo, Monoket
Category: Medications
Created: 12/31/1997
Last Editorial Review: 3/26/2009
isosorbide dinitrate, Isordil Titradose, Dilatrate-SR, Isochron
Source: MedicineNet isosorbide mononitrate Specialty [2009.02.20]
Title: isosorbide dinitrate, Isordil Titradose, Dilatrate-SR, Isochron
Category: Medications
Created: 12/31/1997
Last Editorial Review: 2/20/2009
Published Studies Related to Ismotic (Isosorbide)
Cervical priming in the first trimester: morphological and biochemical effects of misoprostol and isosorbide mononitrate. [2009]
OBJECTIVE: To evaluate morphological changes and inflammatory events in the uterine cervix following presurgical treatment with the prostaglandin analogue misoprostol or the nitric oxide donor isosorbide [generic for Ismotic] mononitrate (IMN). DESIGN: Experimental study. SETTINGS: Sahlgrenska University Hospital, Gothenburg, Sweden. POPULATION OF SAMPLE: Primigravid women (n=32) scheduled for surgical termination of first trimester pregnancy, treated vaginally overnight with either misoprostol (200 microg), IMN (40 mg) or no treatment (controls)... CONCLUSION: The study demonstrates that misoprostol as well as IMN induces morphological changes and inflammatory events of the cervix. Changes of the collagen network were more pronounced in samples obtained from women treated with misoprostol compared to IMN.
Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. [2008.12]
OBJECTIVE: To compare the effectiveness, safety, and affordability of isosorbide [generic for Ismotic] mononitrate with alendronate for postmenopausal osteoporosis... CONCLUSION: Isosorbide mononitrate is comparable to alendronate. Nitric oxide donors may be an effective and affordable therapy to improve bone mineral density.
Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis. [2008.09.20]
OBJECTIVE: To compare the effectiveness, safety, and affordability of isosorbide [generic for Ismotic] mononitrate with alendronate for postmenopausal osteoporosis... CONCLUSION: Isosorbide mononitrate is comparable to alendronate. Nitric oxide donors may be an effective and affordable therapy to improve bone mineral density.
Outpatient cervical ripening with nitric oxide donor isosorbide mononitrate prior to induction of labor. [2008.04]
Objective: To examine the effectiveness and safety of outpatient vaginal administration of isosorbide [generic for Ismotic] mononitrate (IMN) to induce cervical ripening. Methods: A prospective, double-blind, placebo-controlled, randomized clinical trial was conducted on 102 singleton term pregnant women with unfavorable cervices who were randomly assigned to receive outpatient intravaginal IMN or placebo before admission for induction of labor.
Pentaerythrityl tetranitrate and nitroglycerin, but not isosorbide mononitrate, prevent endothelial dysfunction induced by ischemia and reperfusion. [2007.09]
CONCLUSIONS: We show important differences among organic nitrates in their capacity to prevent IR-induced endothelial dysfunction. GTN and PETN, but not ISMN, have this preconditioning effect. The potential clinical implications of these data warrant further investigation.
Clinical Trials Related to Ismotic (Isosorbide)
Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma [Active, not recruiting]
This is a phase II clinical trial in patients who have not received systemic treatment for
follicular non-Hodgkin's lymphoma. The study combines rituximab, an approved drug for this
disease, with AT-101, an experimental drug. The hypothesis is that by adding AT-101 to the
rituximab regimen, improvement to patients' response to the treatment will be observed verses
rituximab alone.
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer [Active, not recruiting]
This is an open label, multicenter Phase I/II study to evaluate the safety and efficacy of
AT-101 in combination with topotecan in relapsed/refractory small cell lung cancer
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With Hormone Refractory Prostate Cancer [Recruiting]
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of
AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate
cancer that are either chemotherapy naive or have received and progressed on a docetaxel
containing regimen,
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer [Recruiting]
This is a double- blind, multicenter, randomized Phase II study to evaluate the efficacy and
safety of AT-101 in combination with docetaxel in relapsed/refractory non-small cell lung
cancer
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) [Recruiting]
This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to
evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus
docetaxel and prednisone plus placebo in the treatment of chemotherapy-naïve metastatic
hormone-refractory prostate cancer, who have received hormonal therapy but not chemotherapy.
|
